VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD Disclosure

6

VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

On June 19, 2017, VBI Vaccines Inc. (the Company) issued a press
release. A copy of the press release is furnished herewith as
Exhibit 99.1 and incorporated by reference in this Item 7.01.

The information disclosed under this Item 7.01, including Exhibit
99.1, hereto, shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, and shall
not be deemed filed with the U.S. Securities and Exchange
Commission nor incorporated by reference into any filing made
under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
99.1* Press Release dated June 19, 2017

* Furnished herewith



VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm   Exhibit 99.1   VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine,…
To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)

VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).

An ad to help with our costs